Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes
Semaglutide GLP-1 aids in weight loss as well
GLP-1 receptor agonists target the centers of the brain that regulate appetite and food intake
Pros: Dual-action mechanism, significant weight loss Cons: Potentially less effective than retatrutide Why Consider Retatrutide at the biostation
US$ 25.55
US$ 29.24
US$ 20.72
US$ 24.01
US$ 28.08
US$ 28.32
